Cardiovascular responses to weight management and sibutramine in high-risk subjects: An analysis from the SCOUT trial

European Heart Journal

Volumn 28, Issue 23, 2007, Pages 2915-2923

  Torp Pedersen, Christian ^a   Caterson, Ian ^b   Coutinho, Walmir ^c   Finer, Nick ^d   Van Gaal, Luc ^e   Maggioni, Aldo ^f   Sharma, Arya ^g   Brisco, Wygenia ^h   Deaton, Roger ^h   Shepherd, Gillian ^h   James, Philip ⁱ  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f ANMCO RESEARCH CENTER   (Italy)

^g MCMASTER UNIVERSITY   (Canada)

^h ABBOTT LABORATORIES   (United States)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cardiovascular outcomes; Randomized trial; Sibutramine; Weight loss

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; SIBUTRAMINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CONSTIPATION; CONTROLLED STUDY; DEATH; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FEMALE; GASTROINTESTINAL DISEASE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOTHESIS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PULSE RATE; SIDE EFFECT; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; SWEATING; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT DURATION; URINE RETENTION; VERTIGO; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA;

AGED; APPETITE DEPRESSANTS; CYCLOBUTANES; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; WEIGHT LOSS;

EID: 36849095595     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm217     Document Type: Article

References (23)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-1727.
2. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res 1998;6(Suppl. 2):51S-209S.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European Society of Cardiology Committee for Practice Guidelines European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10(Suppl. 1):S1-S78.
4. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-1083.
5. Kennedy LMA, Dickstein K, Anker SD, James M, Cook TJ, Kristianson K, Willenheimer R. Weight-change as a prognostic marker in 12 550 patients following acute myocardial infarction or with stable coronary artery disease. Eur Heart J 2006; doi:10.1093/eurheartj/ehl182.
6. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000;84:441-461.
7. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999;23:1016- 1024.
8. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-2120.
9. Astrup A, Chong E. Weight loss produced by sibutramine: a meta-analysis. Int J Obes Relat Metab Disord 2001;23:S104.
10. Sharma AM. Does pharmacologically induced weight loss improve cardiovascular outcome? Sibutramine pharmacology and the cardiovascular system. Eur Heart J 2005;7(Suppl. L):L39-L43.
11. James WPT. The SCOUT study: risk-benefit profile of sibutramine in overweight high risk cardiovascular patients. Eur Heart J 2005;7(Suppl. L):L44-L48.
12. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
13. HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotension-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996;12:127- 137.
14. Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RAH, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002;105:1162-1169.
15. Sever PS, Poulter NR, Dahlöf B, Wedel H for the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol 2005;96(Suppl.):39F-44F.
16. Ersoz HO, Ukinc K, Baykan M, Erem C, Durmus I, Hacihasanoglu A, Telatar M. Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. Int J Obes Relat Metab Disord 2004;28:378-383.
17. Berube-Parent S, Prud'homme D, St-Pierre S, Doucet E, Tremblay A. Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet - exercise intervention. Int J Obes Relat Metab Disord 2001;25:1144-1153.
18. Scholze J. Adipositasbehandlung mit Sibutramin unter Praxisbedingungen. Deutsche Medizinische Wochenschrift 2002;127:606-610.
19. Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients - sibutramine and blood pressure. Clin Auton Res 2005;15:200-206.
20. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002;106:2459-2465.
21. Tank J, Schroeder C, Diedrich A, Szczech E, Haertter S, Sharma AM, Luft FC, Jordan J. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation 2003;107:2949- 2954.
22. Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Krüger N, Srauss A, Stoffels G, Luft FC, Jordan J. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 2006;79:500-508.
23. Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 2002;16:13-19.